Cherry Hill, NJ, United States of America

Charles G Clarke


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Charles G Clarke

Introduction

Charles G Clarke is a notable inventor based in Cherry Hill, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for various medical conditions. His work is characterized by a focus on innovative solutions to complex health issues.

Latest Patents

One of Clarke's most recent patents is titled "Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors." This invention provides compounds of Formula (I) or their stereoisomers, tautomers, or pharmaceutically acceptable salts. These compounds are designed to be selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. The invention also encompasses pharmaceutical compositions that include these compounds and methods for treating thromboembolic and/or inflammatory disorders.

Career Highlights

Clarke is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts. His work has led to the creation of innovative therapeutic options that address critical health challenges.

Collaborations

Throughout his career, Clarke has collaborated with esteemed colleagues, including Donald J P Pinto and Leon M Smith, II. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Charles G Clarke's contributions to the field of pharmaceuticals exemplify the impact of innovation in medicine. His work on factor XIa inhibitors showcases the importance of research in developing effective treatments for serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…